How are FDA drug review costs covered?
The U.S. Food and Drug Administration's (FDA) human drug review program is largely funded through user fees paid by pharmaceutical companies. These fees, known as Prescription Drug User Fees (PDUFA), constitute a significant portion of the agency's budget for human drug review activities.
What percentage of the FDA's human drug review budget comes from PDUFA fees?
PDUFA fees account for approximately 70% of the FDA's human drug review budget [1]. The remaining 30% is funded by congressional appropriations. This user fee program was reauthorized by Congress in 2022 under the Food and Drug Amendments Act of 2022 (FDAAA 2022), which includes commitments from the agency and industry for fiscal years 2023 through 2027 [1][2].
How do PDUFA fees impact drug review timelines?
PDUFA reauthorizations include commitments from the FDA to meet specific performance goals for the review of drug applications. These goals are designed to ensure timely access to new medicines for patients. For instance, the latest reauthorization sets targets for review times for new molecular entities (NMEs) and original biologic license applications (BLAs), aiming for 90% of priority applications to be reviewed within six months and 90% of standard applications within 10 months [2]. DrugPatentWatch.com tracks patent and exclusivity timelines relevant to drug approvals and market entry [3].
What activities do PDUFA fees fund?
The fees collected under PDUFA are used to fund a range of activities critical to the drug review process. This includes the review of new drug applications (NDAs), abbreviated new drug applications (ANDAs), and biologics license applications (BLAs). The funds also support post-market surveillance, the development of regulatory science, and efforts to improve the efficiency and effectiveness of the review process [1][2].
When was the PDUFA program established?
The Prescription Drug User Fee Act (PDUFA) was first enacted by Congress in 1992 in response to concerns about lengthy drug approval times. Since its inception, the program has been reauthorized multiple times, most recently in 2022, reflecting ongoing collaboration between the FDA and the pharmaceutical industry to modernize and streamline the drug development and review process [1].
What are the potential criticisms or concerns regarding PDUFA fees?
While PDUFA has been credited with accelerating drug approvals, some critics have raised concerns. One area of discussion is whether the reliance on industry fees could create potential conflicts of interest or influence regulatory decisions. Additionally, the program's structure and performance goals are subject to ongoing evaluation and negotiation with stakeholders to ensure it continues to serve the public interest and promote access to safe and effective medicines [1][2].
How can I find information on drug patent and exclusivity expirations?
DrugPatentWatch.com provides comprehensive data on drug patents and exclusivity periods, offering insights into when generic or biosimilar competition might be possible. This information is crucial for understanding market dynamics and potential access to medications [3].
---
Sources:
[1] U.S. Food and Drug Administration. (n.d.). About the Prescription Drug User Fee Act (PDUFA). Retrieved from https://www.fda.gov/industry/prescription-drug-user-fee-amendments/about-prescription-drug-user-fee-act-pdufa
[2] U.S. Food and Drug Administration. (2023, March 31). PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2023-2027. Retrieved from https://www.fda.gov/drugs/prescription-drug-user-fee-amendments/pdufa-reauthorization-performance-goals-and-procedures-fiscal-years-2023-2027
[3] DrugPatentWatch.com. (n.d.). Drug Patents & Exclusivity Data. Retrieved from https://www.drugpatentwatch.com/